文献速递关节外科创伤骨科

干细胞联合富血小板血浆有效治疗糖皮质激素性股骨头坏死:一项前瞻性研究

Stem Cells Combined With Platelet-rich Plasma Effectively Treat Corticosteroid-induced Osteonecrosis of the Hip: A Prospective Study.
PubMed 文献 · Clin Orthop Relat Res · 2018-01-01

前瞻性初步系列研究纳入22例(35髋)糖皮质激素性股骨头坏死患者,行髓芯减压后注射浓缩骨髓间充质干细胞联合富血小板血浆。术后3年免于全髋关节置换、任何二次手术及股骨头塌陷的生存率分别为84%、67%、93%,改良Kerboul角由205°±47°改善至172°±48°,Harris髋关节评分由57±12改善至85±15。作者结论认为该联合治疗可改善疼痛与功能,需进一步随机研究确定其疗效。

要点

  • 术后3年免于全髋关节置换生存率84%,免于任何二次手术67%,免于股骨头塌陷93%。
  • 改良Kerboul角平均改善-30°±6°(p=0.01),Harris髋关节评分平均改善28±3(p<0.001)。
  • 需二次手术者术前改良Kerboul 3或4级比例更高(80% vs 13%,OR 26,95%CI 2-296,p=0.005)。

核心结论

  • 作者结论认为,髓芯减压联合浓缩骨髓与富血小板血浆注射可改善疼痛和功能,本系列中超过90%的髋在至少2年时未发生塌陷。
  • 作者认为在本初步研究中,核细胞计数高且改良Kerboul分级低时可见成功结果。
  • 作者指出需要进一步随机研究以确定该术式相对于单纯髓芯减压或非手术治疗的疗效。

研究设计与样本

  • 前瞻性初步系列研究,纳入22例连续患者(35髋;男11例、女11例)糖皮质激素性股骨头坏死,均为塌陷前病变,University of Pennsylvania 1期4髋、2期31髋。
  • 患者平均年龄43岁,平均体重指数31 kg/m²;均行术前及术后X线片和MRI,以改良Kerboul角评估股骨头受累程度。
  • 术中取骨髓行绝对细胞计数和集落形成单位(CFU)检测以评估间充质干细胞数量与活力;平均随访3年(范围2-4年)。
  • 以Kaplan-Meier法按髋分析转为全髋关节置换、二次手术及免于股骨头塌陷的生存率;证据等级为II级,治疗性研究。

主要发现

  • 术后3年免于全髋关节置换生存率为84%(95%CI 75%-93%),免于任何二次手术为67%(95%CI 55%-79%),免于股骨头塌陷为93%(95%CI 76%-98%)。
  • 2例患者(4髋)因持续疼痛但无影像学塌陷征象接受第二次减压及间充质干细胞注射;所有发生塌陷的患者均行全髋关节置换。
  • 改良Kerboul角由术前205°±47°改善至术后172°±48°(平均变化-30°±6°,p=0.01)。
  • 接受二次手术者术前改良Kerboul 3或4级比例更高:80%(4/5)vs 13%(4/30例1或2级;OR 26,95%CI 2-296,p=0.005)。
  • Harris髋关节评分由术前57±12改善至末次随访85±15(平均变化28±3,p<0.001);接受二次手术或全髋关节置换者核细胞浓度较低(5.5×10⁶±2.8×10⁶ cells/mL vs 2.3×10⁶±2.2×10⁶ cells/mL,p=0.02)、CFU较低(13±6 vs 19±7,p=0.04)。

临床怎么用

  • 作者结论认为髓芯减压后注射浓缩骨髓联合富血小板血浆可改善疼痛和功能,本系列中超过90%的髋在至少2年时未发生塌陷。
  • 作者认为核细胞计数高且改良Kerboul分级低的患者中可见成功结果。
  • 作者指出需要进一步随机研究以确定该术式相对于单纯髓芯减压或非手术治疗的疗效。

局限性

  • 作者指出本研究为初步研究,需要进一步随机研究以确定该术式相对于单纯髓芯减压或非手术治疗的疗效。
  • 1例患者(2髋)在术后1年内因与手术无关的原因死亡,5例患者(7髋)在1年随访时未行MRI。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Randomized trials have shown the benefits of injecting bone marrow-derived mesenchymal stem cells (BmMSCs) after standard hip decompression in patients with osteonecrosis of the femoral head. However, the combination of BmMSCs and platelet-rich plasma (PRP) injected into the femoral head after decompression has not been reported previously. This study reports the results in a preliminary series of patients with osteonecrosis of the femoral head treated with BmMSCs plus PRP. QUESTIONS/PURPOSES: (1) What is the survivorship free from reoperation, hip arthroplasty, and femoral head collapse in a preliminary series of patients with osteonecrosis of the femoral head treated with BmMSCs plus PRP? (2) Is there a change in the degree of femoral head involvement based on modified Kerboul angle? (3) What were the scores observed for pain and function at last followup? (4) Was there a difference in survivorship free from reoperation as a function of in vitro MSC count and viability? METHODS: Twenty-two consecutive patients (35 hips; 11 men and 11 women) with corticosteroid-induced osteonecrosis who met study inclusion criteria were enrolled; none declined participation, and none was lost to followup, although one patient (two hips) died within a year of the procedure for reasons unrelated to it, and five patients (seven hips) did not undergo MRI at the 1-year followup. All patients had precollapse osteonecrosis, rated either University of Pennsylvania Stage 1 (n = 4) or Stage 2 (n = 31 hips). Mean age and body mass index were 43 years and 31 kg/m, respectively. Patients underwent pre- and postoperative radiographs and MRI to assess femoral head involvement using the modified Kerboul angle. Absolute cell count and colony-forming unit (CFU) assays were used to assess MSC abundance and viability of the bone marrow obtained at the time of surgery. Patients were followed at regular intervals to assess clinical response to treatment with a mean followup of 3 years (range, 2-4 years). The change in femoral head involvement was assessed with the modified Kerboul angle; the Harris hip score was used to assess clinical outcome; and conversion to THA, reoperation, and survivorship free from femoral head collapse were analyzed with the Kaplan-Meier method on a per-hip basis. RESULTS: Survivorship free from THA, any procedure, and femoral head collapse was 84% (95% confidence interval [CI], 75%-93%), 67% (95% CI, 55%-79%), and 93% (95% CI, 76%-98%), respectively, at 3 years postoperatively; two patients (four hips) underwent a second decompression and MSC injection for persistent pain without signs of radiographic collapse. All patients with collapse underwent THA. The mean modified Kerboul angle improved from 205° ± 47° to 172° ± 48° postoperatively (mean change -30° ± 6°, p = 0.01). A greater proportion of patients who underwent an additional procedure had a modified Kerboul grade of 3 or 4 preoperatively (80% [four of five] versus 13% [four of 30 Grade 1 or 2; odds ratio, 26; 95% CI, 2-296; p = 0.005). Preoperatively the mean Harris hip score was 57 ± 12, which improved to 85 ± 15 (mean change 28 ± 3, p < 0.001) at most recent followup. Patients undergoing a reoperation or THA had a lower mean concentration of nucleated cells/mL (5.5 x 10 ± 2.8 x 10 cells/mL versus 2.3 x 10 ± 2.2 x 10 cells/mL, p = 0.02) and lower mean CFUs (13 ± 6 versus 19 ± 7, p = 0.04) compared with those who did not. CONCLUSIONS: Core hip decompression with injection of concentrated bone marrow plus PRP improved pain and function; > 90% of hips in this series were without collapse at a minimum of 2 years. In this preliminary study, successful results were seen when nucleated cell count was high and modified Kerboul grade was low. Further randomized studies are needed to determine this procedure's efficacy versus core decompression or nonoperative treatment alone. LEVEL OF EVIDENCE: Level II, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Houdek MT, Wyles CC, Collins MS, et al. Stem Cells Combined With Platelet-rich Plasma Effectively Treat Corticosteroid-induced Osteonecrosis of the Hip: A Prospective Study. Clin Orthop Relat Res. 2018. PMID: 29529674. doi:10.1007/s11999.0000000000000033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。